While other healthcare companies including Covidien (NYSE:COV) and Abbott (NYSE:ABT) have seen fit to split their drug and device businesses, it's perhaps lucky for Johnson & Johnson (NYSE:JNJ) shareholders that their company has not gone the same route. While it wasn't really so long ago that JNJ's drug business was struggling, now it's the consumer and device business that need the pick-me-up. Even with the strength of the drug business and the wider healthcare sector, though, it's hard to see a lot of surplus value in the shares at these prices.
Continue reading here:
http://www.investopedia.com/stock-analysis/041713/pharma-doing-all-pulling-johnson-johnson-cov-abt-jnj-mdt-stj-isrg-syk-rhhby-zmh-sny.aspx
Investopedia: Pharma Is Doing All The Pulling For Johnson & Johnson
0 comments:
Post a Comment